This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
FAIR-HF was a randomized, quadruple-masked, parallel phase 3 trial evaluating Ferinject® (ferric carboxymaltose) against normal saline in patients with chronic heart failure and iron deficiency. The registry reports 456 enrolled participants and one primary endpoint assessed 24 weeks after initiation of therapy.
| Feature | FAIR-HF |
|---|---|
| Study acronym | FAIR-HF |
| Phase | Phase 3 |
| Conditions | Chronic Heart Failure; Iron Deficiency; Iron Deficiency Anemia; Anaemia |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Primary purpose | Treatment |
| Enrollment | 456 |
| Number of arms | 2 |
| Lead sponsor | Vifor Pharma |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT00520780 |
2. Clinical Question
The primary statistical question is whether treatment with Ferinject® (ferric carboxymaltose), compared with normal saline, changes the patient-reported global assessment and NYHA functional status 24 weeks after initiation of therapy in patients with chronic heart failure and iron deficiency.
Population
Patients with chronic heart failure and iron deficiency. The registry also lists iron deficiency anemia and anaemia among the conditions.
Intervention
Ferinject® (ferric carboxymaltose).
Comparator
Normal saline (0.9%).
Primary question
How does the randomized comparison affect self-reported patient global assessment and NYHA functional status at 24 weeks?
3. Trial Design
Ferinject®
- Ferinject® (ferric carboxymaltose)
- Drug intervention
Normal saline
- Normal saline (0.9%)
- Drug intervention
4. Trial Timing and Status
Trial initiation
The registry lists 2007-04 as the study start date.
Primary completion
The registry lists 2009-07 as the primary completion date.
Study status
The registry classifies FAIR-HF as completed.
The interval from study start in 2007-04 to primary completion in 2009-07 spans the period during which the trial was conducted. The registry does not provide additional numerical information here about the timing of individual participant enrollment, follow-up, withdrawals, or endpoint assessments.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Primary endpoint | Self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy | 24 weeks |
This endpoint combines two clinically meaningful assessments: a self-reported patient global assessment and NYHA functional status. The time frame is explicitly defined as 24 weeks after initiation of therapy.
6. Planned Analysis
The registry identifies the primary endpoint as self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy. No formal statistical analyses are posted to ClinicalTrials.gov for this endpoint.
How an endpoint of this type is typically analysed
A prespecified analysis of a 24-week outcome would generally compare the randomized treatment groups using an appropriate statistical model for the measurement scale of the endpoint. The exact model depends on how PGA and NYHA functional status are recorded and how the endpoint is operationalized in the statistical analysis plan.
For a continuous outcome, this could be expressed as a difference in means or an adjusted mean difference. For an ordinal outcome, an ordinal regression model or another method appropriate to the ordered categories may be considered. The correct choice depends on the prespecified measurement and analysis framework.
Why the randomized design is important
Randomization creates the principal basis for comparing the treatment groups. If baseline prognostic factors are distributed appropriately through random allocation, differences in the 24-week endpoint can be interpreted as differences associated with randomized treatment assignment, subject to the usual assumptions and limitations of the trial.
Why the 24-week time point matters
The endpoint is explicitly defined at 24 weeks after initiation of therapy. That makes the analysis a fixed-time comparison rather than a survival analysis. Participants' outcomes at the prespecified assessment point, together with the handling of participants who do not have an evaluable assessment, become important components of the statistical analysis.
Analysis population
The registry information available here identifies randomization and enrollment but does not provide the definitions of the analysis populations, such as an intention-to-treat population, per-protocol population, or modified analysis population. Those distinctions can materially affect interpretation of a fixed-time treatment comparison.
7. Statistical Methodology
Randomization
Randomization is the core design feature supporting the comparison between Ferinject® and normal saline. Rather than selecting treatment according to participant characteristics or investigator judgment, randomized allocation establishes treatment groups prospectively and helps balance both measured and unmeasured prognostic factors in expectation.
For a numerical endpoint Y, the treatment contrast can be expressed as the difference between the corresponding group-level outcome measures. The appropriate estimand depends on the endpoint definition and prespecified analysis.
Fixed-time endpoint analysis
The primary endpoint is evaluated at 24 weeks after initiation of therapy. This differs fundamentally from an endpoint such as time to death, where each participant can contribute a different amount of follow-up and censoring is central to the analysis.
Adjustment for baseline information
For a continuous 24-week outcome, analysis of covariance (ANCOVA) is a commonly used approach when baseline measurements of the outcome are available. ANCOVA models the follow-up outcome while accounting for baseline variation, potentially improving precision. However, the registry information does not specify that ANCOVA was used in FAIR-HF, so it should be regarded here as a general statistical framework rather than a documented trial-specific method.
Ordinal outcomes
NYHA functional status is naturally expressed as an ordered functional classification. If the analysis uses its ordinal structure, an ordinal regression approach can preserve more of the information in the ordered categories than simply treating categories as unrelated nominal outcomes. The suitability of such a model depends on the exact endpoint coding and analysis plan.
Confidence intervals
A confidence interval would quantify statistical uncertainty around an estimated treatment effect. For example, if a difference in mean outcome were estimated, its confidence interval would describe the range of values compatible with the specified confidence level under the statistical model and sampling framework.
P-values
A p-value addresses evidence against a specified null hypothesis under the statistical model. It does not describe the size of the treatment effect and does not provide the probability that the null hypothesis is true. A clinically meaningful interpretation therefore requires the estimated treatment effect and its uncertainty, not a p-value alone.
8. Statistical Methods Explained
Why is randomization important for a 24-week comparison?
Randomization establishes treatment assignment before the outcome is observed. This reduces the risk that treatment groups differ systematically because of treatment-selection decisions. For a fixed-time outcome, the resulting comparison is naturally tied to randomized assignment rather than to observational differences between patients who happened to receive different therapies.
Why is this not primarily a Kaplan-Meier analysis?
The registered primary endpoint is assessed 24 weeks after initiation of therapy. Kaplan-Meier estimation is designed for time-to-event outcomes with potentially different follow-up times and censoring. A fixed-time PGA or NYHA comparison instead focuses on the measured status at the prespecified 24-week assessment.
Why might ANCOVA be useful?
If a continuous outcome has a baseline measurement, ANCOVA can compare 24-week outcomes while accounting for baseline differences in the measured variable. This can reduce residual variability and improve precision. It is not appropriate to claim that FAIR-HF used ANCOVA unless that method is documented in the statistical plan.
How would an ordinal NYHA outcome differ from a continuous outcome?
Ordinal categories contain ordering but not necessarily equal numerical distances between categories. Treating them as continuous can impose assumptions about those distances. Ordinal regression can instead model the probability of being at or below particular ordered categories, subject to the assumptions of the chosen model.
What does a confidence interval tell us?
A confidence interval describes uncertainty around an estimated treatment effect under the specified statistical procedure. A narrow interval indicates greater statistical precision than a wide interval, all else equal. It does not describe the range of individual patient responses.
Why is the p-value not an effect-size measure?
The p-value depends on both the observed treatment contrast and the amount of information available. A small p-value can accompany a modest effect in a large study, while a clinically important effect can fail to achieve a small p-value when information is limited. Effect magnitude and precision therefore need to be examined directly.
9. Analysis Population and Missing Assessments
For a fixed 24-week endpoint, missing assessments can be particularly important. Participants who do not have a recorded 24-week PGA or NYHA assessment cannot simply be treated as if their outcome were known. The statistical analysis needs a prespecified rule for defining the analysis population and handling missing observations.
Intention-to-treat principle
An intention-to-treat analysis generally preserves randomized treatment assignment for efficacy comparisons. The ClinicalTrials.gov record does not specify whether or how this principle was operationalized for the primary endpoint.
Missing data
The ClinicalTrials.gov record does not specify a missing-data or imputation method. For a 24-week endpoint, assumptions about missing outcomes can influence the estimated treatment contrast.
Common approaches can include complete-case analysis, multiple imputation, model-based methods, or prespecified rules for particular categories of missingness. These approaches make different assumptions and should not be treated as interchangeable.
10. Masking and Statistical Interpretation
The registry classifies FAIR-HF as quadruple-masked. Masking can reduce the influence of treatment knowledge on aspects of trial conduct and outcome assessment. This is especially relevant when outcomes involve patient-reported assessments, because knowledge of treatment assignment can potentially affect perceptions and reporting.
| Design feature | Registry classification | Statistical relevance |
|---|---|---|
| Allocation | Randomized | Supports a prospective treatment-group comparison. |
| Design model | Parallel | Participants are compared according to parallel randomized groups. |
| Masking | Quadruple | Reduces opportunities for treatment knowledge to influence trial conduct or assessment. |
| Primary purpose | Treatment | The trial is structured to evaluate a treatment intervention. |
11. Endpoint Interpretation
The patient global assessment incorporates the participant's own assessment of their overall status. Because it is self-reported, its interpretation is different from that of an objective laboratory measurement or an independently observed event. The statistical comparison concerns the distribution of the reported outcome under randomized treatment assignment.
NYHA functional status provides an ordered clinical classification of functional limitation. Its ordinal nature matters statistically: the distance between adjacent categories should not automatically be assumed to be numerically equivalent unless the analysis explicitly makes that assumption.
The registry names both self-reported patient global assessment and NYHA functional status in the primary endpoint. A complete statistical interpretation would therefore need the prespecified rule defining how these two components were jointly evaluated, including the statistical estimand and decision criterion.
12. What a Treatment Estimate Would Mean
For a fixed-time endpoint, the treatment effect would normally be expressed using a measure appropriate to the endpoint's scale. If the endpoint were summarized as a continuous score, a mean difference could be used. If it were represented as ordered categories, an ordinal treatment-effect measure could be more appropriate.
Core interpretation principle
A treatment effect describes the magnitude and direction of the difference between randomized groups.
A p-value addresses compatibility with a specified null hypothesis; it does not quantify how large or clinically important the treatment effect is.
Similarly, statistical significance and clinical importance are separate concepts. A complete interpretation would consider the magnitude of the observed difference, its confidence interval, the endpoint's clinical scale, and the prespecified decision framework.
13. Limitations
- No posted numerical efficacy analysis: the ClinicalTrials.gov record does not post statistical estimates, confidence intervals, or p-values for the primary endpoint.
- Endpoint detail: the primary endpoint names PGA and NYHA functional status, but the available registry information does not specify the exact statistical representation or decision rule for the two components.
- Analysis population: the registry information available here does not define the efficacy analysis population.
- Missing data: no missing-data or imputation method is specified in the available registry information.
- Baseline adjustment: the available registry information does not specify whether baseline measurements were incorporated into the primary statistical model.
- Outcome scale: the appropriate model depends on the precise scale and coding of PGA and NYHA functional status.
- Precision: although enrollment is 456, the number of participants with evaluable 24-week assessments is not reported in the available registry information.
14. Why This Trial Matters Statistically
FAIR-HF is a useful statistical teaching case because it illustrates a different problem from the classic time-to-event clinical trial. The primary endpoint is evaluated at a prespecified 24-week time point and incorporates patient-reported and functional-status information. That shifts the analytical focus toward measurement scale, randomized group comparison, missing assessments, and the handling of potentially ordinal outcomes.
| Concept | How it appears in FAIR-HF |
|---|---|
| Randomization | The registry classifies allocation as randomized. |
| Parallel design | The trial has 2 parallel arms. |
| Masking | The registry classifies the study as quadruple-masked. |
| Fixed-time endpoint | The primary endpoint is assessed 24 weeks after initiation of therapy. |
| Patient-reported outcome | The primary endpoint includes self-reported patient global assessment. |
| Ordinal clinical status | The primary endpoint includes NYHA functional status. |
| Analysis population | The registry information available here does not specify the population used for the primary efficacy analysis. |
| Missing data | The available registry information does not specify an imputation strategy. |
| Effect estimation | A suitable treatment contrast depends on the precise outcome scale and prespecified statistical model. |
15. Sources
- ClinicalTrials.gov: NCT00520780 — FAIR-HF.
- PubMed: PubMed record.
- PubMed: PubMed record.
Continue through the Clinical Biostats clinical trial library
Explore additional clinical trial analyses and statistical resources covering trial design, endpoints, estimation, and interpretation.
16. Record Summary
FAIR-HF is a randomized, parallel phase 3 trial with 456 enrolled participants, 2 arms, quadruple masking, and a treatment-focused primary purpose. The intervention was Ferinject® (ferric carboxymaltose), with normal saline (0.9%) as the comparator. The registered primary endpoint was self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy.
Statistically, the key feature is the fixed 24-week clinical outcome. Unlike a time-to-event endpoint, this analysis centers on the measurement recorded at a prespecified follow-up point. The appropriate treatment contrast depends on the exact scale of PGA and NYHA functional status and on the prespecified statistical analysis. Considerations include randomized treatment assignment, outcome measurement, analysis population, missing assessments, and the distinction between effect size, confidence intervals, and p-values.